FWM
ONCE

Focused Wealth Management’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Focused Wealth Management’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-750
Closed -$67K – 762
2017
Q3 		$67K Hold
750
– – 0.02% 203
2017
Q2 		$45K Hold
750
– – 0.02% 295
2017
Q1 		$40K Buy
+750
New +$44.5K 0.02% 307

Other funds holding ONCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Focused Wealth Management's ONCE Position: Q4 2017 in Review

Focused Wealth Management sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2017, closing a stake of 750 shares — an estimated $67K sold.

Focused Wealth Management first reported a position in ONCE in Q1 2017 and held it in 3 quarters. The position peaked at $67K in Q3 2017. 160 funds tracked by Wall St. Rank hold ONCE as of Q4 2017.

  • Focused Wealth Management reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Focused Wealth Management sold 750 Spark Therapeutics, Inc. Common Stock shares in Q4 2017, an estimated $67K.
  • Focused Wealth Management first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2017 and held it in 3 quarters.
  • Focused Wealth Management's Spark Therapeutics, Inc. Common Stock position peaked at $67K in Q3 2017.
  • 160 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2017.

Based on Focused Wealth Management's 13F filing for Q4 2017, filed 13 Feb 2018.